Jeremy Rubinstein, MD, PhD
- Member, Division of Oncology
- Assistant Professor, UC Department of Pediatrics
- jeremy.rubinstein@cchmc.org
- Board Certified
About
Biography
As a pediatric oncologist, I specialize in treating pediatric leukemia and lymphoma, emphasizing the use of cellular therapy. Cellular therapy involves modifying a patient’s own cells or cells from a donor to fight disease.
I have long been inspired by the strength and bravery of children going through cancer diagnosis and treatment. It is an incredibly difficult process. I'm passionate about providing longitudinal care while guiding patients and their families through this challenging time. I strive to treat every patient I meet with the utmost respect, care, patience, honesty and dedication.
My research focuses on using new and emerging cellular therapy techniques to better treat difficult-to-manage leukemias and lymphomas and the management of important side effects such as viral infections. I am the recipient of a St. Baldrick's Fellow research grant from July 2020 to July 2022, looking at the use of T-cell therapy to prevent viral infections.
I love to spend my free time with my wife, son and daughter. I also like to run, read books and play basketball.
Undergraduate: University of Virginia, Charlottesville, VA.
MD/PhD: University of Virginia, Charlottesville, VA.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Interests
Pediatric oncology; leukemia; lymphoma; cellular therapy; post-transplant lymphoproliferative disorder (PTLD)
Services and Specialties
Cancer and Blood Diseases
Interests
Viral infections are a significant source of morbidity and mortality in patients following hematopoietic stem cell transplant and antiviral medications carry high toxicity profiles often with suboptimal response. Dr. Rubinstein's research focuses on the use of virus-specific T cell (VST) therapy to combat a number of viruses seen after both stem cell transplantation and solid organ transplantation. He is involved in numerous clinical trials seeking to optimize the use of this approach and works closely with laboratory-based collaborators to improve knowledge and understanding of their mechanism of action.
Research Areas
Oncology
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Advances. 2022; 6:2897-2907.
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Advances. 2021; 5:3309-3321.
Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Advances. 2020; 4:5745-5754.
Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Biology of Blood and Marrow Transplantation. 2020; 26:e280-e285.
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer. 2023; 70:e30271.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Transplantation and cellular therapy. 2023; 29:305-310.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.
Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy. Pediatric Blood and Cancer. 2023; 70:e30214.
106 GEMCITABINE, OXALIPLATIN, AND ANTI-CD20 THERAPY IS SAFE AND EFFECTIVE IN CHILDREN AND YOUNG ADULTS WITH NON-HODGKIN LYMPHOMA UNFIT FOR INTENSIVE THERAPY. Leukemia Research: clinical and laboratory studies. 2022; 121:s63-s64.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey